Anebulo Pharmaceuticals Inc [NASDAQ: ANEB] loss -6.02% or -0.15 points to close at $2.34 with a heavy trading volume of 149712 shares.
It opened the trading session at $2.47, the shares rose to $2.47 and dropped to $2.33, the range by which the price of stock traded the whole day. The daily chart for ANEB points out that the company has recorded 122.86% gains over the past six months.
If we look at the average trading volume of 52.27K shares, ANEB reached to a volume of 149712 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Anebulo Pharmaceuticals Inc [ANEB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ANEB shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ANEB stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 9.87, with the Price to Cash per share for the same quarter was set at 0.25.
Trading performance analysis for ANEB stock
Anebulo Pharmaceuticals Inc [ANEB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.74. With this latest performance, ANEB shares dropped by -13.01% in over the last four-week period, additionally plugging by 122.86% over the last 6 months – not to mention a rise of 39.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ANEB stock in for the last two-week period is set at 43.96, with the RSI for the last a single of trading hit 0.12, and the three-weeks RSI is set at 0.13 for Anebulo Pharmaceuticals Inc [ANEB]. The present Moving Average for the last 50 days of trading for this stock 2.47, while it was recorded at 2.37 for the last single week of trading, and 1.84 for the last 200 days.
Anebulo Pharmaceuticals Inc (ANEB) Capital Structure & Debt Analysis
According to recent financial data for Anebulo Pharmaceuticals Inc. ( ANEB), the Return on Equity (ROE) stands at -145.11%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -128.22%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Anebulo Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -86.70%, showcasing its effectiveness in deploying capital for earnings.
Anebulo Pharmaceuticals Inc (ANEB) Efficiency & Liquidity Metrics
Based on Anebulo Pharmaceuticals Inc’s (ANEB) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Anebulo Pharmaceuticals Inc (ANEB) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Anebulo Pharmaceuticals Inc. (ANEB) effectively leverages its workforce, generating an average of -$2813333.33 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.93% and a Quick Ratio of 10.93%, indicating strong ability to cover short-term liabilities.
Anebulo Pharmaceuticals Inc [ANEB]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Anebulo Pharmaceuticals Inc posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ANEB.
An analysis of Institutional ownership at Anebulo Pharmaceuticals Inc [ANEB]
There are presently around $54.08%, or 90.95%% of ANEB stock, in the hands of institutional investors. The top three institutional holders of ANEB stocks are: 22NW, LP with ownership of 5.37 million shares, which is approximately 20.6927%. LVW ADVISORS, LLC, holding 0.64 million shares of the stock with an approximate value of $$1.75 million in ANEB stocks shares; and LVW ADVISORS, LLC, currently with $$1.4 million in ANEB stock with ownership which is approximately 1.9707%.
